Table 2.
Metabolic control and QALY for the study population at baseline and after 48 weeks of insulin analog therapy
| Trial arms | ||||||
|---|---|---|---|---|---|---|
| BIAsp 30 (n = 82) | NPH/Reg Insulin (n = 82) | |||||
| Baseline | 48 weeks | P value | Baseline | 48 weeks | P value | |
| HbA1c (%) | 9.55 ± 1.03 | 7.15 ± 0.24 | 0.021 | 9.97 ± 1.52 | 7.62 ± 0.21 | 0.011 |
| FPG (mg/dl) | 208.10 ± 4.51 | 144.33 ± 8.16 | 0.029 | 185.76 ± 12.1 | 132.00 ± 13.2 | 0.027 |
| PPG (mg/dl) | 276.84 ± 9.2 | 211.51 ± 10.3 | 0.032 | 239.25 ± 12.55 | 180.88 ± 12.90 | 0.019 |
| TG (mg/dl) | 183.19 ± 11.33 | 173.44 ± 12.50 | 0.247 | 191.22 ± 55.11 | 170.42 ± 40.18 | 0.631 |
| Total Chol (mg/dl) | 184.41 ± 21.31 | 169.41 ± 15.13 | 0.471 | 176.33 ± 22.30 | 161.28 ± 18.34 | 0.259 |
| LDL (mg/dl) | 103.72 ± 19.70 | 101.89 ± 16.42 | 0.554 | 110.39 ± 14.56 | 98.44 ± 19.45 | 0.131 |
| HDL (mg/dl) | 45.34 ± 11.05 | 49.45 ± 18.65 | 0.398 | 48.55 ± 15.12 | 47.47 ± 19.35 | 0.228 |
| BMI (kg/m2) | 29.37 ± 6.78 | 29.59 ± 3.62 | 0.421 | 31.78 ± 7.52 | 33.88 ± 2.89 | 0.166 |
| QALY | ||||||
| EQ-5D-3 L | 0.59 ± 0.03 | 0.73 ± 0.04 | 0.031 | 0.64 ± 0.11 | 0.66 ± 0.06 | 0.082 |
| VAS | 0.61 ± 0.05 | 0.75 ± 0.06 | 0.026 | 0.69 ± 0.04 | 0.71 ± 0.08 | 0.074 |
Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, HbA1c hemoglobin A1c, TG triglyceride, Chol cholesterol, LDL low density lipoprotein, HDL high density lipoprotein, BMI body mass index, QALY quality adjusted life year, EQ-5D-3 L European quality of life-5 dimensions -3 levels, VAS and visual analogue scale